Omega Therapeutics, Inc. (NASDAQ:OMGA) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its lead product candidate, OTX-2002, for the treatment of hepatocellular carcinoma (HCC).
OTX-2002 is a first-in-class Omega Epigenomic Controller in development for the treatment of hepatocellular carcinoma (HCC).
The company is planning to initiate a Phase 1 clinical trial in the United States to evaluate OTX-2002, following IND approval from the regulatory agency.
Mahesh Karande, President and Chief Executive Officer, commented : This is an important milestone for our Company, an IND achieved in approximately 26 months since we started working on the early constructs in discovery which culminated in OTX-2002. We are excited that this represents the first of many anticipated IND applications and the transition of the company to its next stage.
Omega Therapeutics closed Tuesdays trading at $2.69.
